Scholar Rock Clears FDA Hurdle With First Muscle-Targeted SMA Drug
ISEMBYLD approval moves Scholar Rock into commercialization after a manufacturing setback delayed its first attempt last year.
Makkler Newsroom · Sep 16, 12:17 AM · 2 min read
Scholar Rock Holding Corp. SRRK
NASDAQHealth TechnologyUnited States
$43.21+0.05 (+0.10%)
Market closed· · USD · Data may be delayed
- Day's range
- 42.7644.16
- 52-week range
- 35.5361.76
Financial health
– / 5
Analyst view · 18 firms
Buy16 buy · 2 hold · 0 sell
Avg. target $70.44 (+63.0%)
Prices may be delayed and are for informational purposes only - not investment advice.